Canadian Medical Company Taps 蜜桃APP-Developed Artificial Intelligence for COVID-19 Treatments
June 05, 2020
Research Attracts Investment
By partnering with Skymount, a Calgary-based medical company that recently set up its first U.S. office in Baton Rouge, 蜜桃APP will test new treatments for COVID-19 to help ease symptoms and lower the mortality rate. The treatments were found using an artificial intelligence tool known as DeepDrug鈩�, which was developed at 蜜桃APP.
鈥淭his is a major breakthrough,鈥� said Zubin Kothawala, CEO of Skymount Medical. 鈥淒eepDrug鈩� has the power to perform 15 years of drug discovery and due diligence in 15 days and leads the pack in medical artificial intelligence in terms of accuracy, speed, and performance.鈥�
The interdisciplinary 蜜桃APP experts are also a current semi-finalist for the , a $5 million award for innovative teams using artificial intelligence to tackle global challenges
Artificial intelligence helps map known antiviral peptides (AVPs) to different cell mechanisms by analyzing protein-protein interactions. The AVPs are then ranked by how effectively they can slow the propagation of coronavirus in the human body.
鈥� 蜜桃APP DeepDrug鈩�
鈥淒eepDrug鈩� has the power to perform 15 years of drug discovery and due diligence in 15 days and leads the pack in medical AI in terms of accuracy, speed, and performance.鈥�
Zubin Kothawala, Skymount Medical CEO